Heart Calcium Sensitizer on Morbidity and Mortality of High-risk Surgical Patients with MODS: Systematic Review and Meta-analysis

Overview

Journal Int J Clin Exp Med

Specialty General Medicine

Date 2016 Jan 16

PMID 26770361

Authors

Li Qiao

Chengshan Xu

Xinji Li

Fei Li

Wei Liu

Affiliations

Soon will be listed here.

Abstract

A total of 440 patients from 10 studies were included in a systematic review to evaluate the association between improved survivals from multiple organ dysfunction syndromes in patients undergoing surgical operation. Health Inter Network Initiatives (HINARI), MEDLINE and EMBASE were searched. Exclusion criteria were duplicate publications, non-human experimental studies, and no mortality data. The primary endpoint was postoperative mortality. Levosimendan was found to be associated with a reduction in postoperative mortality (11/235 [4.7%] in the levosimendan group v 26/205 [12.7%] in the control, odds ratio of 0.35 [0.18-0.71], P for effect as 0.003, P for heterogeneity 0.22, and I(2) as 27.4% (440 patients included), cardiac troponin release, and atrial fibrillation. No difference was found in terms of myocardial infarction, acute renal failure, time on mechanical ventilation, intensive care unit, and hospital stay. Calcium-sensitizer for congestive heart failure; Levosimendan has cardioprotective effects that could result in a reduced operative mortality.

References

Thackray S, Easthaugh J, Freemantle N, Cleland J . The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail. 2002; 4(4):515-29. DOI: 10.1016/s1388-9842(02)00041-7. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Hatala R, Keitz S, Wyer P, Guyatt G . Tips for learners of evidence-based medicine: 4. Assessing heterogeneity of primary studies in systematic reviews and whether to combine their results. CMAJ. 2005; 172(5):661-5. PMC: 550638. DOI: 10.1503/cmaj.1031920. View

Tritapepe L, De Santis V, Vitale D, Santulli M, Morelli A, Nofroni I . Preconditioning effects of levosimendan in coronary artery bypass grafting--a pilot study. Br J Anaesth. 2006; 96(6):694-700. DOI: 10.1093/bja/ael082. View

Du Toit E, Hofmann D, McCarthy J, Pineda C . Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model. Heart. 2001; 86(1):81-7. PMC: 1729816. DOI: 10.1136/heart.86.1.81. View

Prentice R . Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989; 8(4):431-40. DOI: 10.1002/sim.4780080407. View

Shah B, Sharma P, Brahmbhatt A, Shah R, Rathod B, Shastri N . Study of levosimendan during off-pump coronary artery bypass grafting in patients with LV dysfunction: a double-blind randomized study. Indian J Pharmacol. 2014; 46(1):29-34. PMC: 3912803. DOI: 10.4103/0253-7613.125161. View

Ruilope L . Telmisartan for the management of patients at high cardiovascular risk. Curr Med Res Opin. 2011; 27(8):1673-82. DOI: 10.1185/03007995.2011.597378. View

Glasziou P, Sanders S . Investigating causes of heterogeneity in systematic reviews. Stat Med. 2002; 21(11):1503-11. DOI: 10.1002/sim.1183. View

10.

Soares M, Feres G, Salluh J . Systemic inflammatory response syndrome and multiple organ dysfunction in patients with acute tumor lysis syndrome. Clinics (Sao Paulo). 2009; 64(5):479-81. PMC: 2694253. DOI: 10.1590/s1807-59322009000500016. View

11.

Alvarez J, Taboada M, Rodriguez J, Caruezo V, Bouzada M, Campana O . [Hemodynamic effects of levosimendan following cardiac surgery]. Rev Esp Anestesiol Reanim. 2005; 52(7):389-94. View

12.

Deeks J . Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med. 2002; 21(11):1575-600. DOI: 10.1002/sim.1188. View

13.

Biondi-Zoccai G, Agostoni P, Abbate A, Testa L, Burzotta F . A simple hint to improve Robinson and Dickersin's highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol. 2005; 34(1):224-5. DOI: 10.1093/ije/dyh311. View

14.

Missant C, Rex S, Segers P, Wouters P . Levosimendan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunction. Crit Care Med. 2007; 35(3):707-15. DOI: 10.1097/01.CCM.0000257326.96342.57. View

15.

Follath F, Cleland J, Just H, Papp J, Scholz H, Peuhkurinen K . Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002; 360(9328):196-202. DOI: 10.1016/s0140-6736(02)09455-2. View

16.

Zangrillo A, Biondi-Zoccai G, Mizzi A, Bruno G, Bignami E, Gerli C . Levosimendan reduces cardiac troponin release after cardiac surgery: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth. 2009; 23(4):474-8. DOI: 10.1053/j.jvca.2008.11.013. View

17.

Levin R, Degrange M, Porcile R, Salvagio F, Blanco N, Botbol A . [The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome]. Rev Esp Cardiol. 2008; 61(5):471-9. View

18.

Mizock B . The multiple organ dysfunction syndrome. Dis Mon. 2009; 55(8):476-526. DOI: 10.1016/j.disamonth.2009.04.002. View

19.

Juni P, Altman D, Egger M . Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ. 2001; 323(7303):42-6. PMC: 1120670. DOI: 10.1136/bmj.323.7303.42. View

20.

Jarvela K, Maaranen P, Sisto T, Ruokonen E . Levosimendan in aortic valve surgery: cardiac performance and recovery. J Cardiothorac Vasc Anesth. 2008; 22(5):693-8. DOI: 10.1053/j.jvca.2008.01.024. View